Hot Stocks in the News – June 17, 2025

June 17, 2025

DENVER, Colo., Jun 17, 2025 (247marketnews.com)- VENU (NYSE:VENU) filed a an 8-K that VENU closed a $10.25 million funding, with an institutional investor, at a $15 equivalent premium to the market, signaling strong investor confidence and where two analysts pegged their Buy/Outperform price targets.

In an interview on the Schwab Network, Founder and CEO J.W. Roth revealed that VENU currently has $1.2 billion in live projects and plans to scale to $3 billion over the next 3–4 years. Roth emphasized the company’s innovative financing model combining public-private partnerships (PPP), fractional ownership sales, and sale-leasebacks.

Please click here to view the interview.

Acurx Pharmaceuticals (NASDAQ:ACXP) surged after publishing positive Phase 2b trial results in Lancet Microbe for its lead antibiotic candidate ibezapolstat, which showed a 94% clinical cure rate with zero recurrences at one month, compared to a 14% recurrence in the vancomycin group. The study reinforces IBZ’s potential as a first-line CDI treatment that preserves gut microbiota, led by Kevin Garey, PharmD, a top expert in C. difficile research.

CERo Therapeutics (NASDAQ:CERO) gained attention after announcing the FDA granted Orphan Drug Designation for CER-1236, its lead AML candidate. The novel engineered T-cell therapy combines phagocytic and cytotoxic mechanisms, offering a unique multi-modal attack against leukemia cells.

Verve Therapeutics (NASDAQ:VERV) shares are trading higher after reports surfaced that Eli Lilly is nearing a $1.3 billion acquisition deal, signaling big pharma’s growing interest in gene-editing platforms, at $10.50/share plus a $3.00 contingent value right (CVR), totaling up to $13.50/share. Verve’s gene-editing therapies, including VERVE-102 for cardiovascular diseases, align with Lilly’s focus.

Salarius Pharmaceuticals (NASDAQ:SLRX) continues to move on momentum as Nasdaq granted Salarius an extension to regain compliance on June 16, sparking the recent volume spikes.

XCF Global (NASDAQ:XCFG) is attempting a rebound after hitting a new 52-week low yesterday. Watch for potential short-covering or bounce plays today.

These tickers are each riding significant catalysts across high-growth sectors, so stay tuned at 247MarketNews.com for real-time alerts and deeper dives.

Please go to https://247marketnews.com/disclaimer/ and https://247marketnews.com/venu-disclosure/ for further disclaimer and disclosure information.

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.

24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.

CONTACT:
24/7 Market News
Editor@247marketnews.com

Related news for (VENU, ACX, CERO, VERV, SLRX, XCFG)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.